Neumora Therapeutics (NMRA) R&D In Process (2023 - 2025)
Neumora Therapeutics' quarterly R&D In Process came in at $5.0 million in Q3 2025, up 525.0% quarter-over-quarter from $800000.0 in Q4 2023.
Neumora Therapeutics has reported R&D In Process for 2 years, with the latest figure at $5.0 million in Q3 2025.
- For the quarter ending Q3 2025, R&D In Process changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2025 stood at $5.0 million (up 525.0% YoY), and the FY2025 full-year result was $5.0 million, changed N/A from the prior year.
- R&D In Process for Q3 2025 stood at $5.0 million, up from $800000.0 in the prior quarter.
- The five-year high for R&D In Process was $5.0 million in Q3 2025, with the low at $800000.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 500,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 101.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.00 Mn |
| Dec 31, 2023 | 800,000.00 |